ResMed (RMD) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 20.4%. For ResMed, the consensus EPS estimate for the current year has increased 2.8% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy). Looking more specifically, Mind Medicine (MindMed) Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 505 individual stocks and currently sits at #91 in the Zacks Industry ...

General and administrative expenses were $10.5 million for the quarter ended March 31, 2024, compared to $8.3 million for the same period in 2023, an increase of $2.2 million. The increase was primarily attributable to increased stock-based compensation expense of $1.1 million and an increase of $0.7 million in personnelrelated expenses due to an increase in headcount to support the growth of our business. Thanks. Super helpful. Got it. Thanks so much. Elaine Kim Thanks. That's helpful. Just one quick one, ...

For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option.Small-cap stocks can have exciting potential. At low valuations, there may be much more upside for investors than there can be for large tech stocks with market caps in excess of $1 trillion. One red-hot stock of late has been Mind Medicine (MNMD -4.62%). Shares of the psychedelic biotech company have jumped by close to 140% already this year. Here's why there may be room for the stock to rise even high ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q4 2023 Earnings Conference Call February 28, 2024 8:00 AM ET Company Participants Rob Barrow - Chief Executive Officer Schond Greenway - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Charles Duncan - Cantor Fitzgerald Francois Brisebois - Oppenheimer Sumant Kulkarni - Canaccord Genuity Elemer Piros - Rodman & Renshaw Operator Good morning, and welcome to the Mind Medicine Full Year 2023 Financial Results and Corporate Up ...

Company Participants Conference Call Participants Operator For opening remarks, I would like to introduce Rob Barrow, CEO of MindMed. Please go ahead. Thank you, and good afternoon, everyone. Welcome to our third quarter 2023 financial results and corporate update conference call. The press release reporting our financial results is available in the Investors and Media section of our website and our quarterly report on Form 10-Q for the quarter ended September 30, 2023, will be filed today with the Securiti ...

On a related note, in June, FDA released draft guidance for developing drugs in psychonomic drug corn. Notably, this guidance highlights the reality that dose response is not well understood to the drug class and It also reinforces our high degree of confidence in our team's ability to launch and enroll future studies in a very efficient manner. Patient dosing enrollment for our Phase 2b trial in GAD is progressing well across our 20 active sites and we expect to complete study enrollment in the third quart ...

Yes. Rob Barrow Thanks, Elemer. Operator Thank you. Your next question comes from Patrick Trucchio H.C. Wainwright. Patrick, please go ahead. But you are not examining efficacy based on reduction in depressive symptoms. Francois Brisebois Okay, great. And then in terms of the R&D Day that you mentioned would still be in the second quarter, is that where you plan on sharing more details about your commercialization plans for each product? Or is that kind of at a later time? Rob Barrow I think as we think abo ...

Mind Medicine (MindMed), Inc. (NASDAQ:MNMD) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Robert Barrow - CEO & Director Schond Greenway - CFO Daniel Karlin - Chief Medical Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Elemer Piros - ROTH Capital Partners Patrick Trucchio - H.C. Wainwright & Co. Sepehr Manochehry - Eight Capital Operator Good day, and welcome to the Mind Medicine Third Quarter 2022 Financial Results and Corporate Update Conferen ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Robert Barrow - Chief Executive Officer Schond Greenway - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Elemer Piros - ROTH Capital Partners Patrick Trucchio - H.C. Wainwright Sepehr Manochehry - Eight Capital Operator Good afternoon and welcome to the Mind Medicine Second Quarter 2022 Financial Results and Corporate Update Conference Call. At t ...

ADY (good MindMed Corporate Overview June 2022 This preentation (It's "Presentabler") in observer prepend by Wird Medical (nc., Weddled' or the Canepor(") solely (co ricrentdon) presses. Lose of Wirlients co or of their aucassons, representatives or gants molworny restor to the occuracy or corpoplenes of op ridenced by risemation corndined on this Presentablion ond diosility to qu represen resentation This proventables riski not constitute on offe, no constitution of an other of the valentifies. This Presen ...